| Literature DB >> 25985445 |
T Bölling1, G Braun-Munzinger2, S Burdach3, G Calaminus2, A Craft4, O Delattre5, M-C L Deley6, U Dirksen2, B Dockhorn-Dworniczak7, J Dunst8, S Engel2, A Faldum9, B Fröhlich2, H Gadner10, U Göbel11, G Gosheger12, J Hardes12, D S Hawkins13, L Hjorth14, C Hoffmann2, H Kovar10, J Kruseova15, R Ladenstein10, I Leuschner16, I J Lewis17, O Oberlin18, M Paulussen19, J Potratz2, A Ranft2, C Rössig2, C Rübe20, R Sauer21, O Schober22, A Schuck23, B Timmermann24, F Tirode5, H van den Berg25, F van Valen26, V Vieth27, N Willich23, W Winkelmann12, J Whelan28, R B Womer29.
Abstract
Curative therapies for Ewing sarcoma have been developed within cooperative groups. Consecutive clinical trials have systematically assessed the impact and timing of local therapy and the activity of cytotoxic drugs and their combinations. They have led to an increase of long-term disease-free survival to around 70% in patients with localized disease. Translational research in ES remains an area in which interdisciplinary and international cooperation is essential for future progress. This article reviews current state-of-the art therapy, with a focus on trials performed in Europe, and summarizes novel strategies to further advance both the cure rates and quality of survival. © Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh：
Year: 2015 PMID： 25985445 DOI： 10.1055/s-0035-1545263
Source DB: PubMed Journal: Klin Padiatr ISSN： 0300-8630 Impact factor: 1.349